New IQVIA data confirms double-digit growth for Milgamma and Magnerot in a key European market.
Böblingen / Sofia, March 2026 – Wörwag Pharma continues its growth trajectory in the international Consumer Healthcare segment. The latest IQVIA Sell In Retail Audit 2025 shows a very positive performance for two of the company’s established OTC brands in Bulgaria: Milgamma and Magnerot.
According to the audit, Milgamma ranked #2 among OTC regulated medicines in Bulgaria in 2025. The brand reached €10.7 million in retail sales, recording 12.2% growth compared to 2024. Magnerot achieved the #7 position, generating €7.7 million in sales and growing by 23.2% year-on-year. With both brands ranked among the Top 10 OTC regulated products, Wörwag Pharma further strengthens its presence in one of Europe’s important Consumer Healthcare markets.
Wörwag Pharma has been active in Bulgaria since the establishment of its local affiliate in 1995 and is today recognized as one of the established companies in the country’s Consumer Healthcare segment. The affiliate is supported by an experienced local team whose market expertise and strong execution have been key contributors to the company’s growth.
At corporate level, Wörwag Pharma ranks #10 in the Bulgarian Consumer Healthcare market, with a 2.6% market share and 19.3% value growth — making the company the fastest growing player within the national Top 10.
Statement from the Country Manager Bulgaria
“These results reflect the strong market position of our brands and the dedication of our local team. Achieving two Top 10 placements is an important milestone and highlights the relevance of our portfolio in the Bulgarian Consumer Healthcare market.”
- Lora Ivcheva, Country Manager Bulgaria
Wörwag Pharma will continue to focus on sustainable growth in international Consumer Healthcare markets, supported by long-term brand development and strong regional expertise.